ABBV
AbbVie Inc.
Price performance
Sep 18, 2026About
Company activity
42 events| Time | Ticker | Type | Event | Qty | Price | Value |
|---|---|---|---|---|---|---|
| 09/03 | ABBV | 8-K | AbbVie Completes Acquisition of Apogee Therapeutics | — | — | — |
| 08/18 | ABBV | 8-K | AbbVie Completes Underwritten Public Offering of Senior Notes | — | — | — |
| 08/05 | ABBV | 8-K | AbbVie Inc. Announces Major Debt Offering | — | — | — |
| 07/31 | ABBV | 8-K | AbbVie Reports Strong Q2 2026 Financial Results and Announces Acquisition of Apogee Therapeutics | — | — | — |
| 07/06 | ABBV | 8-K | AbbVie Inc. Announces Acquired IPR&D and Milestones Expense Impacting Q2 2026 Earnings | — | — | — |
| 06/22 | ABBV | 8-K | AbbVie to Acquire Apogee Therapeutics in $10.9 Billion Deal | — | — | — |
| 05/12 | ABBV | 8-K | AbbVie Inc. Announces Results of 2026 Annual Meeting of Stockholders | — | — | — |
| 04/29 | ABBV | 8-K | AbbVie Reports First-Quarter 2026 Financial Results and Raises Guidance | — | — | — |
| 04/03 | ABBV | 8-K | AbbVie Updates 2026 Earnings Guidance Due to Acquired IPR&D and Milestones Expense | — | — | — |
| 03/04 | ABBV | 8-K | AbbVie Completes Underwritten Public Offering of Senior Notes | — | — | — |
| 02/26 | ABBV | 8-K | AbbVie Inc. Announces Issuance of Senior Notes | — | — | — |
| 02/04 | ABBV | 8-K | AbbVie Reports 2025 Financial Results and 2026 Outlook | — | — | — |
| 01/07 | ABBV | 8-K | AbbVie Discloses Impact of Acquired IPR&D and Milestones Expense on Q4 2025 Earnings | — | — | — |
| 10/31/25 | ABBV | 8-K | AbbVie Announces Third-Quarter 2025 Financial Results and Raises Full-Year Guidance | — | — | — |
| 10/03/25 | ABBV | 8-K | AbbVie Announces Expected Third Quarter 2025 Acquired IPR&D and Milestones Expense | — | — | — |
| 09/11/25 | ABBV | 8-K | AbbVie Announces Settlement of Litigation Over Upadacitinib | — | — | — |
| 07/31/25 | ABBV | 8-K | AbbVie Reports Q2 2025 Financial Results with Adjusted EPS of $2.97 | — | — | — |
| 07/03/25 | ABBV | 8-K | AbbVie Expects Earnings Impact Due to Acquired IPR&D and Milestones Expense | — | — | — |
| 05/13/25 | ABBV | 8-K | AbbVie Expands Board and Announces Leadership Changes | — | — | — |
| 04/25/25 | ABBV | 8-K | AbbVie Reports First-Quarter 2025 Financial Results and Key Business Updates | — | — | — |
| 04/03/25 | ABBV | 8-K | AbbVie Announces Preliminary Q1 2025 Financial Results and Adjusts Guidance | — | — | — |
| 02/26/25 | ABBV | 8-K | AbbVie Inc. Completes Senior Notes Offering | — | — | — |
| 02/19/25 | ABBV | 8-K | AbbVie Inc. Announces Issuance of Senior Notes | — | — | — |
| 02/14/25 | ABBV | 8-K | AbbVie Elects CEO as New Chairman | — | — | — |
| 02/05/25 | ABBV | 8-K | AbbVie Inc. Enters into Revolving Credit Agreement | — | — | — |
| 01/31/25 | ABBV | 8-K | AbbVie Reports 2024 Financial Results and Provides 2025 Outlook | — | — | — |
| 01/10/25 | ABBV | 8-K | AbbVie Announces Significant Impairment Charge for Emraclidine Asset | — | — | — |
| 01/06/25 | ABBV | 8-K | AbbVie Announces Fourth-Quarter and Full-Year 2024 Earnings Guidance Including Acquired IPR&D and Milestones Expense | — | — | — |
| 12/13/24 | ABBV | 8-K | AbbVie Appoints New Senior Vice President, Controller | — | — | — |
| 10/30/24 | ABBV | 8-K | AbbVie Reports Q3 2024 Results with Increased Revenues and Adjusted EPS | — | — | — |
| 10/03/24 | ABBV | 8-K | AbbVie Inc. Discloses Third-Quarter Earnings Impact | — | — | — |
| 09/10/24 | ABBV | 8-K | AbbVie Inc. Updates By-laws and Provides Financial Exhibits | — | — | — |
| 07/25/24 | ABBV | 8-K | AbbVie Reports Q2 2024 Financial Results and Raises Guidance | — | — | — |
| 07/03/24 | ABBV | 8-K | AbbVie Inc. Reports Unfavorable Impact on Earnings Due to Acquired IPR&D and Milestones Expense | — | — | — |
| 05/08/24 | ABBV | 8-K | AbbVie Appoints New CEO and Announces 2024 Annual Meeting Results | — | — | — |
| 04/26/24 | ABBV | 8-K | AbbVie Announces First-Quarter 2024 Results and Leadership Transition | — | — | — |
| 04/03/24 | ABBV | 8-K | AbbVie Announces Expected Earnings Miss Due to Acquired IPR&D and Milestones Expense | — | — | — |
| 02/26/24 | ABBV | 8-K | AbbVie Announces $15 Billion Senior Notes Offering | — | — | — |
| 02/20/24 | ABBV | 8-K | AbbVie Appoints Robert A. Michael as New CEO | — | — | — |
| 02/12/24 | ABBV | 8-K | AbbVie Completes Acquisition of ImmunoGen | — | — | — |
| 02/02/24 | ABBV | 8-K | AbbVie Reports 2023 Financial Results and Announces Acquisitions | — | — | — |
| 01/05/24 | ABBV | 8-K | AbbVie Announces 2023 Fourth Quarter Earnings Guidance Adjustment Due to Acquired IPR&D and Milestones Expense | — | — | — |
ABBV filing record
AbbVie Inc. (ABBV): 42 8-K filings summarized, the most recent on Sep 3, 2026.
What the 8-K filings said
- Sep 3, 2026 · high impact
AbbVie Inc. has completed its acquisition of Apogee Therapeutics, Inc. for approximately $10.9 billion in cash. The acquisition, which is expected to negatively impact AbbVie's adjusted diluted earnings per share by $0.14 in 2026 and $0.46 in 2027, aims to strengthen AbbVie's immunology pipeline with new assets…
AbbVie Completes Acquisition of Apogee Therapeutics - Aug 18, 2026 · medium impact
On August 18, 2026, AbbVie Inc. completed its previously announced underwritten public offering of various series of senior notes totaling $5.5 billion in aggregate principal amount. The notes, with maturities ranging from 2028 to 2066, were issued under AbbVie's Indenture and are intended to fund a portion of the…
AbbVie Completes Underwritten Public Offering of Senior Notes - Aug 5, 2026 · medium impact
On August 4, 2026, AbbVie Inc. announced the issuance of various senior notes totaling approximately $9.93 billion in net proceeds. The offering includes floating rate notes and fixed-rate notes due between 2028 and 2066. The proceeds will be used to fund the acquisition of Apogee Therapeutics, Inc., pay related fees…
AbbVie Inc. Announces Major Debt Offering - Jul 31, 2026 · high impact
AbbVie Inc. reported strong second-quarter 2026 financial results, with worldwide net revenues of $16.990 billion, an increase of 10.2 percent on a reported basis. Diluted EPS on a GAAP basis was $2.03, and adjusted diluted EPS was $3.65. The company also announced a definitive agreement to acquire Apogee Therapeutics…
AbbVie Reports Strong Q2 2026 Financial Results and Announces Acquisition of Apogee Therapeutics - Jul 6, 2026 · high impact
AbbVie Inc. reported that acquired IPR&D and milestones expense of $291 million on a pre-tax basis is expected to negatively impact both GAAP and non-GAAP diluted earnings per share by $0.17 for the second quarter of 2026. The company has updated its 2026 guidance to reflect this expense, with the full-year adjusted…
AbbVie Inc. Announces Acquired IPR&D and Milestones Expense Impacting Q2 2026 Earnings
SEC filings in the last five years
- 67 Form 8-K
- 13 Form 10-Q
- 5 Form 10-K
- 1 Form 8-K/A